Results 81 to 90 of about 4,565 (192)

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, Volume 19, Issue 9, Page 2715-2729, September 2025.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

First-line alectinib for ALK-positive lung cancer: is there room for further improvement?

Drugs in Context, 2018
In the present editorial we describe the therapeutic achievements in the treatment of patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). We focus on the major breakthroughs we have been witnessing in this
Alfredo Addeo, Giulio Metro
doaj   +1 more source

ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis.

PLoS ONE, 2020
BackgroundWe sought to assess the relative effects of individual anaplastic lymphoma kinase (ALK) inhibitors for the treatment of non-small cell lung cancer (NSCLC).MethodsWe searched MEDLINE, Embase, Cochrane CENTRAL, and grey literature (July 23, 2019)
Jesse Elliott, Zemin Bai, Shu-Ching Hsieh, Shannon E Kelly, Li Chen, Becky Skidmore, Said Yousef, Carine Zheng, David J Stewart, George A Wells   +9 more
doaj   +1 more source

Efficacy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel Therapy in Patients With Genetic Alterations in Non‐Small Cell Lung Cancer

Thoracic Cancer, Volume 16, Issue 18, September 2025.
This retrospective study evaluated 61 patients with advanced NSCLC harboring genetic alterations treated with ABCP therapy. Efficacy and safety were comparable between the EGFR (n = 33) and other (n = 28) groups. Notably, patients with high PD‐L1 expression (≥ 50%) derived a significant progression‐free survival benefit.
Tsunehiro Tanaka, Motohiro Tamiya, Akito Miyazaki, Kiyohide Komura, Shun Futamura, Takahisa Kawamura, Kei Kunimasa, Takako Inoue, Kazumi Nishino   +8 more
wiley   +1 more source

The role of brigatinib in crizotinib-resistant non-small cell lung cancer

Cancer Management and Research, 2018
Laura Mezquita, David Planchard Medical Oncology Department, Gustave Roussy, Villejuif, France Abstract: Despite the advances in new targeted therapies in ALK positive population, most patients progress under ALK inhibitors within first 2 years ...
Mezquita L, Planchard D
doaj  

Managing Pharmacotherapy in People Living With HIV and Concomitant Malignancy. [PDF]

, 2019
Objective: To describe data with selected malignancies in people living with HIV (PLWH) and HIV in individuals affected by both conditions and to summarize drug-drug interactions (DDIs) with clinical recommendations for point-of-care review of ...
Chan, Alexandre, Klibanov, Olga, Olin, Jacqueline L, Spooner, Linda M   +3 more
core   +1 more source

Belizatinib is a potent inhibitor for non-small cell lung cancers driven by different variants of EML4-ALK fusion proteins carrying L1196M-mutations [PDF]

, 2022
Structural fusions of EML4 with ALK kinase might lead to signaling abnormalities that drive NSCLC. Although approved specific ALK inhibitors have led to excellent initial responses in ALK positive NSCLC patients, acquired resistance to these inhibitors ...
Li, Pan
core  

Anaplastic large cell lymphoma in children and adolescents

British Journal of Haematology, Volume 207, Issue 2, Page 336-349, August 2025.
Summary Anaplastic lymphoma kinase (ALK)‐positive anaplastic large‐cell lymphoma (ALCL) accounts for >95% of ALCL cases in children and adolescents. The first description of ALCL as a CD30‐positive lymphoma in 1985 was followed by the detection of chromosomal translocations involving the ALK gene at chromosome 2p23.
Eric J. Lowe, Wilhelm Woessmann
wiley   +1 more source

Mechanistic Insights and Therapeutic Potentials of Ubiquitin‐Proteasome System in Non‐Small Cell Lung Cancer

Cell Proliferation, Volume 58, Issue 7, July 2025.
Lung cancer development involves mechanisms like reduced EGFR/EGF ubiquitination driving cancer cell behaviors and immune evasion via loss of PD‐1/PD‐L1 ubiquitination. Balancing ubiquitination and deubiquitination may be a potential therapeutic strategy. ABSTRACT Non‐small cell lung cancer (NSCLC) remains a leading cause of cancer mortality.
Guangyao Zhou, Jiaxiong Tan, Pengpeng Zhang, Zhaokai Zhou, Lianmin Zhang, Zhenfa Zhang   +5 more
wiley   +1 more source

Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in patients with ALK‐positive lung adenocarcinoma: Implications of CNS penetration rate of brigatinib

Thoracic Cancer
We present the case of a 34‐year‐old Japanese man with anaplastic lymphoma kinase (ALK)‐positive non‐small cell lung cancer and brain metastases. After central nervous system (CNS) disease progression with alecintib and brigatinib, treatment with ...
Yuki Sato, Yoshiharu Sato, Kei Irie, Shigeki Nanjo, Shigeo Hara, Satoru Fujiwara, Keisuke Tomii   +6 more
doaj   +1 more source